Market Overview:
The global oxidative stress assay market size reached US$ 789.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,368.4 Million by 2028, exhibiting a growth rate (CAGR) of 9.5% during 2023-2028.
Oxidative stress is a health condition wherein excessive production of oxygen-derived free radicals within a cell or organism overwhelms the intrinsic antioxidant defenses. It causes oxidative damage to proteins, lipids and nucleic acids, which can further lead to the development of cancer, asthma, ischemia, diabetes, and cardiovascular and neurodegenerative diseases. It is assessed using a number of assays that help healthcare researchers gain a better understanding of the mechanisms and responses of the condition.
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Free radicals can be produced due to biological factors, unhealthy dietary habits and air pollution. This, in confluence with the rising number of individuals who smoke and consume alcohol, is escalating the risk of developing oxidative stress, which, in turn, is strengthening the market growth. Apart from this, the development of various pathologic conditions and acceleration of the aging process on account of oxidative stress is also bolstering the market growth. Furthermore, the growing biopharmaceutical industry, increasing investments in the research and development (R&D) activities and technological advancements, such as high-content screening for drug discovery, are acting as other major factors stimulating the market growth. Moreover, oxidative stress is also being considered as a major factor contributing to the severity of the coronavirus disease (COVID-19). It is also being evaluated as a probable cause of multi-organ failure among patients. The ongoing studies on the interrelation between the disease and oxidative stress are expected to positively influence the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global oxidative stress assay market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product, technology, test type and end user.
Breakup by Product:
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Reagents and Consumables
- Instruments
- Services
Breakup by Technology:
- ELISA (Enzyme-Linked Immunosorbent Assay)
- Flow Cytometry
- Chromatography
- Microscopy
- High-Content Screening
- Label-Free Detection
- Others
Breakup by Test Type:
- Indirect Assays
- Protein-Based Assays
- Lipid-Based Assays
- Nucleic Acid-Based Assays
- Antioxidant Capacity Assays
- Glutathione Assays
- Ascorbic Acid Assays
- Cell-Based Exogenous Antioxidant Assays
- Enzyme-Based Assays
- Reactive Oxygen Species-Based Assays
Breakup by End User:
- Pharmaceutical Industry
- Research Institutes
- Others
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abcam PLC, AMS Biotechnology (Europe) Ltd., Biovision Inc. (Boai NKY Medical Holdings Ltd.), Cell Biolabs Inc., Enzo Biochem Inc., ImmunoChemistry Technologies LLC, Merck KGaA, Oxford Biomedical Research, Promega Corporation, Qiagen N.V. and Thermo Fisher Scientific Inc.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Million |
Segment Coverage |
Product, Technology, Test Type, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abcam PLC, AMS Biotechnology (Europe) Ltd., Biovision Inc. (Boai NKY Medical Holdings Ltd.), Cell Biolabs Inc., Enzo Biochem Inc., ImmunoChemistry Technologies LLC, Merck KGaA, Oxford Biomedical Research, Promega Corporation, Qiagen N.V. and Thermo Fisher Scientific Inc. |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global oxidative stress assay market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global oxidative stress assay market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the test type?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global oxidative stress assay market and who are the key players?
- What is the degree of competition in the industry?